ABN AMRO Bank N.V. Has $1.41 Million Stock Holdings in Pfizer Inc. $PFE

ABN AMRO Bank N.V. increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 78.6% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 49,998 shares of the biopharmaceutical company’s stock after purchasing an additional 22,000 shares during the quarter. ABN AMRO Bank N.V.’s holdings in Pfizer were worth $1,407,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Kepler Cheuvreux Suisse SA bought a new position in shares of Pfizer during the 3rd quarter valued at $16,613,000. Mackenzie Financial Corp boosted its holdings in Pfizer by 119.6% in the third quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock worth $79,157,000 after purchasing an additional 1,691,773 shares in the last quarter. Penn Davis Mcfarland Inc. increased its position in Pfizer by 50.9% during the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock worth $4,266,000 after buying an additional 57,777 shares during the last quarter. Ameriprise Financial Inc. increased its position in Pfizer by 48.2% during the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after buying an additional 5,978,927 shares during the last quarter. Finally, Danske Bank A S bought a new position in Pfizer during the third quarter valued at about $81,298,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.27 on Monday. The company has a market cap of $138.35 billion, a price-to-earnings ratio of 18.53 and a beta of 0.34. The business has a 50 day moving average price of $25.94 and a 200 day moving average price of $26.29. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the previous year, the business posted $0.92 EPS. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. Pfizer’s payout ratio is 131.30%.

Analysts Set New Price Targets

PFE has been the subject of several recent analyst reports. Citigroup upped their price target on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. Cantor Fitzgerald reissued a “neutral” rating on shares of Pfizer in a research note on Monday, June 1st. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a report on Monday, March 2nd. CICC Research initiated coverage on Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price for the company. Finally, Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a report on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded Pfizer’s Ibrance label for frontline maintenance in advanced breast cancer, a regulatory win that could support use of the drug and modestly improve Pfizer’s oncology revenue outlook. FDA expands Pfizer’s Ibrance label for frontline maintenance in advanced breast cancer
• Positive Sentiment: Pfizer declared its third-quarter 2026 dividend of $0.43 per share, reinforcing its appeal for income-focused investors and signaling continued confidence in cash generation. Pfizer Declares Third-Quarter 2026 Dividend
• Neutral Sentiment: Pfizer Ventures participated in a $62 million Series B for Oblenio Bio, highlighting the company’s broader innovation strategy, though the investment is not likely to have an immediate material impact on PFE shares. Oblenio Bio Closes $62 Million Series B…
• Neutral Sentiment: Pfizer halted a tafamidis bioequivalence study, which appears to be a study update rather than a major commercial setback, so the market reaction is likely limited unless further details emerge. Pfizer Halts Tafamidis Bioequivalence Study
• Negative Sentiment: Recent investor concern remains tied to Pfizer’s mixed oncology pipeline news, especially the failed Phase 3 sigvotatug vedotin lung cancer study, which has pressured sentiment around the company’s long-term growth narrative. Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.